UBE2DNL
Putative ubiquitin-conjugating enzyme E2 D2-like protein
Also known as: U2D2L_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for UBE2DNL in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
75 residues, UniProt reviewed canonical sequence.
>Q8IWF7|UBE2DNL
1 MALKLIHKEF LELARDPQPH CSAGPVWDDM LHWQATITRP NDSSYLGGVF FLKFPSDYLF
61 KPPKIKFTNG IYHQRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against UBE2DNL can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.44
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Protein domainsUniProt · Pfam · InterPro
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads UBE2DNL as an antibody target. Whether an autoantibody or antibody against UBE2DNL could matter depends on whether native UBE2DNL is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
UBE2DNL is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label UBE2DNL as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...